The Medicaid expansion under the Patient Protection and Affordable Care Act resulted in a 19% annual increase in Medicaid-insured cancer patients participating in publicly funded clinical trials, according to researchers from Fred Hutchinson Cancer Center, the SWOG Statistics and Data Management Center and Columbia University.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
